MCID: SYS054
MIFTS: 12

Systemic Lupus Erythematosus with Nephritis 3

Aliases & Classifications for Systemic Lupus Erythematosus with Nephritis 3

MalaCards integrated aliases for Systemic Lupus Erythematosus with Nephritis 3:

Name: Systemic Lupus Erythematosus with Nephritis 3 54
Systemic Lupus Erythematosus with Nephritis, Susceptibility to, 3 13

External Ids:

OMIM 54 607967

Summaries for Systemic Lupus Erythematosus with Nephritis 3

MalaCards based summary : Systemic Lupus Erythematosus with Nephritis 3, is also known as systemic lupus erythematosus with nephritis, susceptibility to, 3. An important gene associated with Systemic Lupus Erythematosus with Nephritis 3 is SLEN3 (Systemic Lupus Erythematosus With Nephritis 3). The drugs Cyclophosphamide and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include b cells and kidney.

Description from OMIM: 607967

Related Diseases for Systemic Lupus Erythematosus with Nephritis 3

Diseases in the Systemic Lupus Erythematosus with Nephritis 2 family:

Systemic Lupus Erythematosus with Nephritis 1 Systemic Lupus Erythematosus with Nephritis 3

Symptoms & Phenotypes for Systemic Lupus Erythematosus with Nephritis 3

Clinical features from OMIM:

607967

Drugs & Therapeutics for Systemic Lupus Erythematosus with Nephritis 3

Drugs for Systemic Lupus Erythematosus with Nephritis 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
2
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Hormone Antagonists Phase 4,Phase 3,Phase 2
6 Hormones Phase 4,Phase 3,Phase 2
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
11 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
12 beta-endorphin Phase 4
13 Adrenocorticotropic Hormone Phase 4
14 Melanocyte-Stimulating Hormones Phase 4
15
Azathioprine Approved Phase 3,Phase 2 446-86-6 2265
16
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
17
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
18
Abatacept Approved Phase 2, Phase 3,Phase 1 332348-12-6 10237
19
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
20
belimumab Approved Phase 3 356547-88-1 5957 10451420
21
Infliximab Approved Phase 2, Phase 3 170277-31-3
22
Prednisone Approved, Vet_approved Phase 2, Phase 3, Phase 1 53-03-2 5865
23 Prednisolone acetate Phase 3,Phase 2
24 glucocorticoids Phase 3,Phase 2
25 Methylprednisolone acetate Phase 3,Phase 2
26 Methylprednisolone Hemisuccinate Phase 3,Phase 2
27 Gastrointestinal Agents Phase 3,Phase 2
28 Neuroprotective Agents Phase 3,Phase 2
29 Dermatologic Agents Phase 2, Phase 3
30 Peripheral Nervous System Agents Phase 3,Phase 2
31 Immunoglobulins Phase 3,Phase 2,Phase 1
32 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
33 Prednisolone hemisuccinate Phase 3,Phase 2
34 Prednisolone phosphate Phase 3,Phase 2
35 Anti-Inflammatory Agents Phase 3,Phase 2
36 Antiemetics Phase 3,Phase 2
37 Protective Agents Phase 3,Phase 2
38 Antimetabolites Phase 2, Phase 3, Phase 1
39 Antibodies Phase 3,Phase 2,Phase 1
40 Autoantibodies Phase 2, Phase 3
41 Antimetabolites, Antineoplastic Phase 2, Phase 3, Phase 1
42 Autonomic Agents Phase 3,Phase 2
43 Calcineurin Inhibitors Phase 3,Phase 2
44 Antineoplastic Agents, Hormonal Phase 3,Phase 2
45 Pharmaceutical Solutions Phase 3,Phase 2
46
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
47
Etanercept Approved, Investigational Phase 2 185243-69-0
48 Cyclosporins Phase 2
49 Anti-Infective Agents Phase 2,Phase 1
50 Antifungal Agents Phase 2

Interventional clinical trials:

(show all 29)

id Name Status NCT ID Phase Drugs
1 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
2 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
3 A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) Completed NCT00626197 Phase 3 corticosteroids;cyclophosphamide;mycophenolate mofetil;ocrelizumab;placebo
4 Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease Completed NCT00035308 Phase 3 Abetimus sodium (LJP 394)
5 Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis Recruiting NCT01639339 Phase 3 Standard therapy
6 Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis Suspended NCT01773616 Phase 3 Oral prednisolone;Rituximab;Mycophenolate mofetil;Methyl prednisolone
7 CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis Terminated NCT02514967 Phase 3 Blisibimod;Placebo
8 TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Terminated NCT00368264 Phase 2, Phase 3 infliximab;placebo
9 Study of LJP 394 in Lupus Patients With History of Renal Disease Terminated NCT00089804 Phase 3 abetimus sodium (LJP 394) and/or placebo solution;abetimus sodium (LJP 394);Phosphate-buffered saline
10 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis Terminated NCT00430677 Phase 2, Phase 3 Corticosteroids (prednisone or prednisolone);Abatacept;Abatacept;Mycophenolate mofetil (MMF);Abatacept
11 CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis Withdrawn NCT02074020 Phase 3 Blisibimod;Placebo
12 Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis Withdrawn NCT00336414 Phase 3 cyclophosphamide-prednisone-azathioprine
13 Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis Withdrawn NCT00539799 Phase 3 prednisolone;Placebo
14 Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis Withdrawn NCT01288664 Phase 3 ADVAGRAF
15 Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE) Unknown status NCT00698191 Phase 1, Phase 2
16 Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus Completed NCT02021513 Phase 2
17 Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study Completed NCT00976300 Phase 2 Cyclosporine A;Cyclophosphamide
18 Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus Completed NCT00556192 Phase 2 rituximab
19 Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Completed NCT00094380 Phase 1, Phase 2 CTLA4-IgG4m (RG2077);Cyclophosphamide
20 Etanercept for the Treatment of Lupus Nephritis Terminated NCT00447265 Phase 2 Etanercept;Lupus Treatment- Standard of Care;Placebo
21 Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis Completed NCT00818948 Phase 1 AMG 811
22 Cyclophosphamide and Fludarabine to Treat Lupus Nephritis Completed NCT00001676 Phase 1 SQ Fludarabine
23 Humanized LL2IGG to Treat Systemic Lupus Erythematosus Completed NCT00011908 Phase 1 hLL2 (Epratuzumab)
24 Monoclonal Antibody Treatment for Systemic Lupus Erythematosus Completed NCT00046774 Phase 1 MRA 003 US
25 Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis Enrolling by invitation NCT03174587 Phase 1
26 Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases Terminated NCT00849745 Phase 1
27 Anti-ficolin-3 Autoantibodies in Lupus Nephritis Completed NCT02625831
28 Anti-ficolin-2 Autoantibodies in Lupus Nephritis Completed NCT03063281
29 Detection of Annexin A2 in Systemic Lupus Erythematosus Not yet recruiting NCT03031925

Search NIH Clinical Center for Systemic Lupus Erythematosus with Nephritis 3

Genetic Tests for Systemic Lupus Erythematosus with Nephritis 3

Anatomical Context for Systemic Lupus Erythematosus with Nephritis 3

MalaCards organs/tissues related to Systemic Lupus Erythematosus with Nephritis 3:

39
B Cells, Kidney

Publications for Systemic Lupus Erythematosus with Nephritis 3

Variations for Systemic Lupus Erythematosus with Nephritis 3

Expression for Systemic Lupus Erythematosus with Nephritis 3

Search GEO for disease gene expression data for Systemic Lupus Erythematosus with Nephritis 3.

Pathways for Systemic Lupus Erythematosus with Nephritis 3

GO Terms for Systemic Lupus Erythematosus with Nephritis 3

Sources for Systemic Lupus Erythematosus with Nephritis 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....